ArticleAnnals of surgical oncology2022
Correction to: Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.
Abstract readPublished Erratum
In one paragraph
Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review.Frontiers in oncology · 2024Pooled it
- Application of indocyanine green-mediated fluorescence molecular imaging technology in liver tumors resection: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).Nature communications · 2025Trial
- Data-driven prognostic factors analysis and personalized follow-up strategies for post-progression survival in locally advanced esophageal squamous cell carcinoma after definitive chemoradiotherapy.Annals of medicine · 2026Article
- Development and validation of a nomogram to predict recurrence after hepatectomy in overweight patients with hepatocellular carcinoma: a retrospective cohort study.BMC gastroenterology · 2026Article
- Impact of three-dimensional hepatic models on oncological outcomes and survival after hepatectomy: Prognostic factor analysis in a retrospective cohort.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Multiomics and multi-region spatial transcriptome analysis reveal cellular networks and pathways associated with HCC recurrence.JHEP reports : innovation in hepatology · 2026Article
- Prognostic Models for Small Hepatocellular Carcinoma Using Inflammatory Indices and Machine Learning: A Propensity Score-Matched Study.International journal of general medicine · 2026Article
- The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China.Frontiers in pharmacology · 2026Article
- Establishment and Validation of a Nomogram Based on Inflammation-Immunity-Nutrition Biomarker Scores to Predict Postoperative Early Recurrence in Patients with Hepatocellular Carcinoma: A Multicenter Study.Journal of hepatocellular carcinoma · 2026Article
- Effectiveness and Safety of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective Real-World Study in China.Clinical Medicine Insights. Oncology · 2026Article
- Long-term survival after multimodal therapy for advanced hepatocellular carcinoma: a case report.Frontiers in immunology · 2026Article
- A prognostic model based on gamma-glutamyl transpeptidase-derived neutrophil-platelet for predicting intrahepatic recurrence in hepatocellular carcinoma.Discover oncology · 2025Review
- Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma.World journal of gastrointestinal surgery · 2025Article
- Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.Langenbeck's archives of surgery · 2025Article
- Integrating CEUS Imaging Features and LI-RADS Classification for Postoperative Early Recurrence Prediction in Solitary Hepatocellular Carcinoma: A Machine Learning-Based Prognostic Approach.Journal of hepatocellular carcinoma · 2025Article
- Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.Frontiers in immunology · 2025Article
- Prognostic analysis of different postoperative adjuvant therapies for patients with hepatocellular carcinoma after radical resection with high-risk recurrence factors: a multicenter real-world retrospective study.Frontiers in immunology · 2025Article
- Article
Corrections and comments
- Erratum for
Authors and funding
20 authors.
Lan-Qing YaoDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Zheng-Liang ChenDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zi-Han FengDepartment of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Yong-Kang DiaoDepartment of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
Chao LiDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Hai-Ying SunDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Jian-Hong ZhongDepartment of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Ting-Hao ChenDepartment of General Surgery, Ziyang First People's Hospital, Ziyang, Sichuan, China.
Wei-Min GuThe First Department of General Surgery, The Fourth Hospital of Harbin, Harbin, Heilongjiang, China.
Ya-Hao ZhouDepartment of Hepatobiliary Surgery, Pu'er People's Hospital, Pu'er City, Yunnan, China.
Wan-Guang ZhangDepartment of Hepatic Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Hong WangDepartment of General Surgery, Liuyang People's Hospital, Changsha, Hunan, China.
Yong-Yi ZengDepartment of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Han WuDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Ming-Da WangDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Xin-Fei XuDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Timothy M PawlikDepartment of Surgery, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
Wan Yee LauDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China.
Feng ShenDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China. fengshensmmu@gmail.com.
Tian YangDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China. yangtianehbh@smmu.edu.cn.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
35430669What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.